Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Total Current Liabilities (2021 - 2026)

TriSalus Life Sciences has reported Total Current Liabilities over the past 6 years, most recently at $11.8 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities changed 0.28% year-over-year to $11.8 million; the TTM value through Mar 2026 reached $11.8 million, changed 0.28%, while the annual FY2025 figure was $11.5 million, 12.43% up from the prior year.
  • Total Current Liabilities for Q1 2026 was $11.8 million at TriSalus Life Sciences, up from $11.5 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $32.4 million in Q4 2022 and troughed at $1.7 million in Q2 2022.
  • A 5-year average of $10.3 million and a median of $10.2 million in 2024 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: surged 1920.27% in 2022 and later plummeted 54.61% in 2023.
  • Year by year, Total Current Liabilities stood at $32.4 million in 2022, then plummeted by 54.61% to $14.7 million in 2023, then plummeted by 30.36% to $10.2 million in 2024, then increased by 12.43% to $11.5 million in 2025, then increased by 2.5% to $11.8 million in 2026.
  • Business Quant data shows Total Current Liabilities for TLSI at $11.8 million in Q1 2026, $11.5 million in Q4 2025, and $10.9 million in Q3 2025.